JP2021529796A5 - - Google Patents

Info

Publication number
JP2021529796A5
JP2021529796A5 JP2021500040A JP2021500040A JP2021529796A5 JP 2021529796 A5 JP2021529796 A5 JP 2021529796A5 JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021500040 A JP2021500040 A JP 2021500040A JP 2021529796 A5 JP2021529796 A5 JP 2021529796A5
Authority
JP
Japan
Prior art keywords
fzd
binding region
wnt
lrp5
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040687 external-priority patent/WO2020010308A1/en
Publication of JP2021529796A publication Critical patent/JP2021529796A/ja
Publication of JP2021529796A5 publication Critical patent/JP2021529796A5/ja
Priority to JP2023186681A priority Critical patent/JP2024001292A/ja
Pending legal-status Critical Current

Links

JP2021500040A 2018-07-05 2019-07-05 多特異性Ｗｎｔ代替分子及びその使用 Pending JP2021529796A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186681A JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Ｗｎｔ代替分子及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862694339P 2018-07-05 2018-07-05
US62/694,339 2018-07-05
US201862782122P 2018-12-19 2018-12-19
US62/782,122 2018-12-19
US201962797772P 2019-01-28 2019-01-28
US62/797,772 2019-01-28
PCT/US2019/040687 WO2020010308A1 (en) 2018-07-05 2019-07-05 Multi-specific wnt surrogate molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186681A Division JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Ｗｎｔ代替分子及びその使用

Publications (2)

Publication Number Publication Date
JP2021529796A JP2021529796A (ja) 2021-11-04
JP2021529796A5 true JP2021529796A5 (https=) 2022-07-12

Family

ID=69059929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500040A Pending JP2021529796A (ja) 2018-07-05 2019-07-05 多特異性Ｗｎｔ代替分子及びその使用
JP2023186681A Pending JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Ｗｎｔ代替分子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023186681A Pending JP2024001292A (ja) 2018-07-05 2023-10-31 多特異性Ｗｎｔ代替分子及びその使用

Country Status (10)

Country Link
US (1) US20210292422A1 (https=)
EP (2) EP3820906B1 (https=)
JP (2) JP2021529796A (https=)
CN (2) CN112566940B (https=)
AU (1) AU2019297522B2 (https=)
CA (1) CA3104526A1 (https=)
DK (1) DK3820906T3 (https=)
ES (1) ES3058239T3 (https=)
PL (1) PL3820906T3 (https=)
WO (1) WO2020010308A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CN117946267A (zh) * 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7550647B2 (ja) * 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CA3144499A1 (en) * 2019-07-02 2021-01-07 Surrozen Operating, Inc. Monospecific anti-frizzled antibodies and methods of use
CA3170340A1 (en) * 2020-02-24 2021-09-02 Surrozen Operating, Inc. Wnt super agonists
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CA3204321A1 (en) * 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
EP4457242A4 (en) * 2021-12-31 2025-12-31 Surrozen Operating Inc SPECIFIC COMPOSITE OF A WNT RECEIVER AND ASSOCIATED METHOD
EP4719454A2 (en) * 2023-05-29 2026-04-08 Surrozen Operating, Inc. Wnt surrogate agents and methods for lacrimal gland regeneration

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP2386577A3 (en) 2006-06-21 2012-05-02 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
BRPI0820327A2 (pt) * 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
EP2220247A4 (en) 2007-11-16 2011-10-26 Nuvelo Inc ANTIBODY AGAINST LRP6
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP2393917B1 (en) 2009-02-03 2016-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells.
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
AU2015314771B2 (en) 2014-09-12 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
WO2016205566A1 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2016205551A2 (en) 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6
WO2017127933A1 (en) 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
US11421028B2 (en) 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US11773171B2 (en) * 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
JP7550647B2 (ja) * 2018-02-14 2024-09-20 アントレラ セラピューティクス インコーポレイテッド Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用

Similar Documents

Publication Publication Date Title
JP2021529796A5 (https=)
JP2021508247A5 (https=)
JP2021508683A5 (https=)
CN111655729B (zh) 抗卷曲蛋白抗体和使用方法
CN112566940B (zh) 多特异性wnt替代分子和其用途
JP2023113950A (ja) Ｗｎｔサロゲート分子及びその使用
JP6647208B2 (ja) 抗ｉｌ−１７抗体、その生産および使用のための方法
JP7317016B2 (ja) 抗ｌｒｐ５／６抗体及び使用方法
JP2017522888A (ja) 多重特異性抗体
CN103649118A (zh) 双特异性结合剂
JP2023504699A (ja) 治療および診断のための新規な分子
JP2010526028A5 (https=)
RU2009133789A (ru) Способы лечения глазных болезней
JP2026016376A5 (https=)
CA2935285A1 (en) Anti-pcsk9-glp-1 fusions and methods for use
JP2014511174A (ja) Ａｐｏｅ免疫療法
JP2022553830A (ja) Ｎ末端ｓｃＦｖ多重特異性結合分子
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
JP2023549854A5 (https=)
JP2025134864A5 (https=)
CN107074963A (zh) 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体
JP2025517360A (ja) トランスフェリン受容体結合ドメイン及びそれを含むタンパク質
WO2011038575A1 (en) Novel antibody treatment
JP2023535840A (ja) 抗原結合タンパク質
WO2024225446A1 (ja) 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物